OSL •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 16:27
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeOSL
Market Capitalization250.04 mln
Float1,069 mln
Earnings Date09/23/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.45
Low leverage
Pre-Tax Margin
-69%
Severely loss-making
ROE
-12.68
Negative
Dividend Yield
0.00%
No dividend
Business Description
SoftOx Solutions AS is a Norwegian pharmaceutical company focused on developing new products to prevent and treat infections. Its lead product, SoftOx Inhalation Solution, is currently in Phase II clinical trials for treating ventilator-associated pneumonia and other airway infections. The company is also working on a broader range of antimicrobial treatments designed to fight bacteria, viruses, and fungi. Founded in 2012, SoftOx is based in Fornebu, Norway.
